Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Updates in metastatic and early-stage breast cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.06.19
Views: 188

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Dr Harold Burstein speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the latest research in breast cancer.

He explains the role of CDK4/6 inhibitors in ER-positive, advanced breast cancer and describes the findings obtained from the MONALEESA-7 trial.

For early-stage patients, Dr Burstein explains the latest findings from the TAYLORx trial, which showed no benefit for chemotherapy.

He also notes the importance of genetic testing and recurrence score testing.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation